Skip to main content
Clinical Trials/EUCTR2013-003234-32-DE
EUCTR2013-003234-32-DEActive, not recruitingPhase 1

Pathological changes in the myocardial microvasculature - a MR-based quantification - Myo-Mikro-Quant

niversitätsklinikum Münster0 sites125 target enrollmentStarted: March 24, 2014Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
125

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Inclusion Criteria

  • •- cardiac disease with suspected microvasculopathy (hypertension, chronic myocardial infarction, hypertrophic cardiomyopathy, post-heart transplantation, cardiac dystrophinopathy)
  • •- age >18 years
  • •- ability to give written informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 125
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

  • •- contraindications to magnetic resonance imaging
  • •- contraindications to Feraheme or Magnevist
  • •- asthma / allergic predisposition
  • •- pregnancy

Investigators

Sponsor
niversitätsklinikum Münster

Similar Trials